Efficacy and Safety of a Traditional Chinese Herbal Formula Xuefu Zhuyu Decoction for Hypertension

Pengqian Wang, MD, Xingjiang Xiong, MD, and Shengjie Li, MD

Abstract: The cardioprotective role of xuefu zhuyu decoction (XZD), a well-known classical herbal formula, has been documented for hypertension treatment recently. This study aims to summarize the efficacy and safety of XZD in treating hypertension.

Seven databases were searched to identify randomized controlled trials evaluating the efficacy of XZD in hypertensive patients. Fifteen studies involving 1364 hypertensive patients were included. All studies compared XZD and antihypertensive drugs with antihypertensive drugs used alone.

In all, 15 studies reported significant effects of XZD for lowering blood pressure compared with the control group (P < 0.05), and 7 studies reported significant effects of XZD for improving symptoms compared with the control group (P < 0.00001). Meanwhile, studies reported XZD was more efficacious than antihypertensive drugs in improving total cholesterol, triglycerides, low-density lipoprotein cholesterol, homocysteine, hemorrhage, carotid intima-media thickness, and left ventricular mass index (P < 0.05). No severe adverse event was reported.

This meta-analysis provides evidence that XZD is beneficial for hypertension. Although concerns regarding selective bias and methodologic flaws were raised, our findings suggest XZD as a new candidate cardioprotective drug for hypertension, which should be given priority for future preclinical and clinical studies.

INTRODUCTION

Hypertension is defined as a systolic blood pressure (SBP) of ≥140 mm Hg or a diastolic blood pressure (DBP) of ≥90 mm Hg and/or the current use of antihypertensive medication. Epidemiologic surveys have identified a strong association between hypertension and cardio- and cerebrovascular diseases. The estimated number of the affected world’s adult population was 26.4% (972 million) in 2000, and the rates are expected to increase to 29.2% (1.56 billion) by 2025. It has become a major contributor to death and disability from heart and vascular diseases. Antihypertensive therapy, especially when combined with effective lipid-lowering therapy, reduces the cardiovascular morbidity and mortality rates; however, the current status of treatment is unsatisfactory. Hence, additional therapeutic approaches with comparatively few adverse effects are gaining increasing popularity worldwide.

Since the publication of Scientific Statement on Alternative Approaches to Lowering Blood Pressure by American Heart Association and Clinical Expert Consensus Documents on Integrating Complementary Medicine Into Cardiovascular Medicine by American College of Cardiology, there has been growing clinical interests in the benefits, harm, and potential herb–drug interactions of complementary and alternative medicine (CAM) for hypertension, including qigong, tai chi, baduanjin exercise, yoga, massage, acupuncture, moxi-ibution, cupping, dietary supplements, and herbal medicine products. As one of the most important components of CAM, traditional Chinese medicine (TCM) has been used for thousands of years and is still being widely practiced. The study of Chinese herbal formulae for promoting blood circulation and removing blood stasis (PBCRBS) for cardiovascular diseases is the active area of research focus within TCM and integrative medicine in East Asia. Recently, Chinese herbal medicine for PBCRBS as a CAM approach has been well recognized in treating hypertension.

The authors have no conflicts of interest to disclose.

DOI: 10.1097/MD.000000000001850
of some traditional Chinese patent medicine for PBCRBS, which have been approved by China Food and Drug Administration for hypertension, was also summarized for clinical recommendations. Thus, PBCRBS-based Chinese herb and formulae have been exploited as an important therapy for hypertension.

Xuefu Zhuyu Decoction (XZD), a well-known PBCRBS-based traditional Chinese classical herbal formula, is recorded in the medical classic *Yi Lin Gai Cuo* by the Chinese physician Wang Qingren (1768–1831) approximately 200 years ago. The multiple cardiovascular protective actions of XZD with no adverse effects have been documented recently. It is efficient in lowering blood pressure (BP) and alleviating BP-related symptoms caused by qi stagnation and blood stasis syndrome according to TCM theory. XZD is composed of 11 Chinese herbs: Peach Kernel (Taoren, Persicae Semen), Safflower Flower (Honghua, Flos Carthami Tinctorii), Chinese Angelica Root (Danggu, Radix Angelicae Sinensis), Rehmannia (Di Huang, Radix Rehmanniae Glutinosae), Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong), Red Peony Root (Chi Shao, Radix Rubræ Paeoniae Lactiflorae), Achyranthes Root (Niu Xi, Achyranthis Bidentatae Radix), Root of the Balloon Flower (Jiegeng, Platycodi Radix), Thorowax Root (Chaihu, Radix Bupleuri), Orange Fruit (Zhihe, Fructus Aurantii), and Liquorice Root (Gan Cao, Radix Glycyrrhizae), with 5-hydroxymethyl-2-furaldehyde, hydroxysafflor yellow A, amygdalin, biflavonoids, paenoflavanoids, liquiritin, ferulic acid, naringin, hesperidin, neohesperidin, isoliquiritigenin, and glycyrrhizin as the major active compounds. The mechanism of XZD for hypertension lies in inhibition of renin–angiotensin–aldosterone system, improvement of endothelial function and prethrombotic state, inhibition of vascular remodeling, and prevention of myocardial fibrosis. Numerous clinical trials have been published reporting the beneficial effects of XZD for hypertension in China; however, no systematic review specifically addressing XZD has been conducted. Thus, a systematic review and meta-analysis of the current available randomized controlled trials (RCTs) was considered appropriate and timely. Given this background, this study aims to comprehensively examine the efficacy and safety of XZD for hypertension.

**METHODS**

This systematic review is conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.

**ELIGIBILITY CRITERIA**

**Types of Studies**

We only included RCTs in this systematic review, regardless of publication date or language. Animal studies were not considered.

**Types of Participants**

Only hypertensive patients were included. No restriction on sex, age, or ethnicity was predefined. Hypertension should be diagnosed clinically according to the criteria documented in the seventh report of the Joint National Committee or other guidelines and definitions.^

**Types of Interventions**

RCTs that examined the effect of XZD either used alone or in combination with western medicine comparing with placebo, no treatment or western medicine were identified. Participants in the treatment group should be treated by XZD-based formula or XZD combined with western medicine. Participants in the control group should be treated by placebo, no treatment or western medicine. The western medicine used in the treatment group should be the same as the controls in the category, dosage and method of administration. Studies were excluded if other CAM therapies beyond Chinese herbal medicine, including yoga, Tai Chi, qigong, acupuncture, moxibustion, cupping and massage, were used in either the treatment group or control group; if other Chinese herbal medicine therapies were used in the control group; if the efficacy of XZD on BP outcome measure was not reported; and if duplicate publication reporting the same conclusions were identified. The definition of XZD-based formula was XZD used alone or the modified XZD based on TCM theory. We have not set any restriction on blinding and treatment duration.

**Types of Outcome Measures**

As antihypertensive therapy is the cornerstone of hypertension treatment, the primary outcome measures were defined as SBP, DBP, and categorical BP at the end of the treatment course. China Food and Drug Administration has adopted 3 classifications to evaluate the therapeutic effects of TCM on categorical BP, which were documented in the Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine (GCRN DTCM). They were as follows: (1) significant improvement—DBP decreased by 10 mm Hg and reached the normal range; (2) improvement—DBP decreased by <10 mm Hg but reached the normal range; and (3) no improvement—BP was not decreased. The secondary outcome measurements were defined as symptoms, blood lipids, homocysteine (Hcy), hemorheology, carotid intima-media thickness (IMT), left ventricular mass index (LVMI), and adverse events.

**Search Strategy**

Relevant publications were electronically searched in 7 databases: Cochrane Library (1996–May 2015), PubMed (1959–May 2015), Embase (1966–May 2015), Chinese Biomedical Literature Database (1978–May 2015), Wanfang database (1985–May 2015), VIP Information Database (1989–May 2015), and China National Knowledge Infrastructure (1979–May 2015). We also manually searched the references of identified studies and ongoing registered clinical trials to retrieve unpublished articles. No restriction on publication language and status was preset. The following search terms were used: (“high blood pressure” OR “hypertension” OR “blood pressure” OR “gao xue ya” OR “xue ya”) AND (“xuefu zhuyu decoction” OR “xuefu zhuyu tang”) AND (“clinical trial” OR “randomized controlled trial” OR “randomised controlled trial” OR “lin chuang yan jiu” OR “lin chuang shi yan”).

**Study Selection**

The titles and abstracts of all the selected articles were independently screened by 2 reviewers according to the eligibility criteria listed above. Duplicate publications were removed accordingly. Then, full texts of potentially relevant articles were retrieved for further assessment. Disagreements were resolved by consultation with a third reviewer.

**Data Extraction**

Basic information of the eligible studies were extracted by 2 reviewers independently using a standardized data extraction
form. The extracted details included the following: (1) basic information of the studies—title, authors’ name, and publication time; (2) basic characteristics of the enrolled patients—age, sexuality, sample size, diagnosis criteria of hypertension and TCM syndrome, baseline difference, and BP before the treatment; (3) basic characteristics of the studies—methodologic quality, interventions in the treatment and control groups, compositions, dosage and administration methods of XZD-based formula, intention-to-treat analysis, and treatment duration; and (4) primary and secondary outcome measures—SBP, DBP, categorical BP, symptoms, blood lipids, HCY, hemorheology, IMT, LVMI, and adverse events. The correspondence authors of the included studies were contacted by e-mail, fax, and telephone number to obtain the missing data.

Quality Assessment
The methodologic quality of the eligible trials was assessed using the Cochrane Collaboration’s tool.52 The criteria from the Cochrane Handbook for Systematic Reviews of Interventions is composed of the following 8 items: (1) adequate sequence generation; (2) concealment of allocation; (3) blinding of the patient; (4) blinding of the investigator; (5) blinding of the assessor; (6) incomplete outcome data addressed (intention-to-treat analysis); (7) free of selective reporting; and (8) other potential threat to validity. Two reviewers independently conducted the quality assessment. The third party was consulted if disagreements were identified.

Data Synthesis
Comparison between XZD and antihypertensive drugs (XPAD) and antihypertensive drugs alone was performed in this review. Outcome measures after treatment were presented as weighted mean difference (WMD) with 95% confidence interval (CI) for continuous outcomes, and risk ratio (RR) with 95% CI for dichotomous outcomes. Heterogeneity of effect sizes was tested using the I² statistics. A random-effects model was adopted to assess the effects of XZD-based formula for hypertension across trials if substantial heterogeneity was observed (I² > 50% or P < 0.1); otherwise, a fixed-effects model was used. A funnel plot was used to examine the publication bias. P < 0.05 was considered to be statistically significant. All of data in this meta-analysis were synthesized using the Review Manager software (RevMan, Version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

RESULTS
Study Selection
Among the 254 studies identified in the literature search, 118 duplicate publications were excluded. After reading the titles and abstracts, 110 articles were excluded because they were case studies, case series, animal experiments, or nonhypertensive patients. Then, 26 full-text articles were assessed for eligibility and we excluded 11 trials because of the following reasons: 2 articles did not meet the inclusion criteria; 2 articles were duplicate publications; 2 articles had no control groups; intervention in 4 articles included other herbal therapies; and 1 article had no BP data for extraction. Ultimately, 15 eligible studies involving a total of 1364 patients with hypertension were identified in the review.53–67 The flow diagram of study selection and identification was summarized in Figure 1.

Study Characteristics
The descriptive information of the included trials and subjects in this review was summarized in Tables 1 and 2. All of 15 trials were conducted in a single center of China and published in Chinese between 2001 and 2015. The sample size ranged from 60 to 128 with a mean size of 91. All patients enrolled were diagnosed as hypertension, which was based on criteria of World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension-1999,53–55,59,63,64,66,67 Chinese Guidelines for the Management of Hypertension-2010 (CGMH-2010),56,65 GCRN DTCM,57 and Chinese Guidelines for the Management of Hypertension-2005 (CGMH-2005).58,60–62 The diagnostic criteria of TCM syndrome was reported in 10 trials, including GCRN DTCM,53,54,56–58,61,65 Traditional Chinese Medicine-Syndrome Differentiation Criteria (TCM-SDC),55,66 and Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine-2008 (GDT CIDCM-2008).62 The age of the enrolled hypertensive patients ranged from 31 to 83 years old. No significant difference on baseline was identified in all the studies. All trials compared XZD with no treatment control, that was, XPAD versus antihypertensive drugs. Treatment duration ranged from 10 days to 24 weeks. One trial reported the dropouts61 and no trial reported source of funding. Interventions of XZD and antihypertensive drugs were all given orally. The dosage of XZD was 1 dose/d in all trials. The components of XZD-based formula in each study were depicted in Table 3. BP outcomes were reported in all the enrolled studies, with continuous BP in 9 trials53–61 and categorical BP in 6 trials.52–67 The symptoms outcomes were reported in 7 trials.55–57,59,61,66,67 The outcomes of blood lipids were reported in 4 trials.53,55,56,57,66 The serum HCY level was reported in 1 trial.62 The outcomes of hemorheology were reported in 2 trials.57,61 The outcome of IMT was reported in 1 trial.53 The LVMI outcome was reported in only 1 trial.58 Adverse events were reported in 3 trials.57,59,61

Methodologic Quality
The assessment of methodologic quality of each included trial was summarized in Table 4. Among them, 5 trials declared how to generate the random sequence58,59,61,62,65; however, the other 10 trials only mentioned randomization in the text without detailed information. Details regarding concealment of allocation and blinding of patient, investigator and assessor were unclear in all the studies. One trial provided the number and reasons of dropouts61 and the other 14 trials reported that all the enrolled subjects had completed the trial; however, both selective reporting and other potential threat to validity can not be assessed due to insufficient information provided in the original trials. Additionally, no study reported the methods of sample size calculation and follow-up.

OUTCOME MEASURES
BP
The effectiveness of XZD on BP was evaluated in all of the 15 trials. Continuous BP was used in 9 trials in this meta-analysis.53–61 There were 385 patients in the XZD groups and 371 patients in the antihypertensive drugs groups, respectively. A random-effects model was used for statistical analysis according to the test of heterogeneity (SBP: chi-square = 74.80, P < 0.00001, I² = 89%; DBP: chi-square = 46.20, P < 0.00001,
The combined effects of these 9 independent trials showed a significant lowering effects of XZD on SBP (WMD = -6.99 mm Hg; 95% CI: -10.62 to -3.36, \( P = 0.0002 \)) and DBP (WMD = -4.44 mm Hg; 95% CI: -6.45 to -2.44, \( P < 0.0001 \)) in patients with hypertension when compared with antihypertensive drugs alone (Fig. 2A and B). Categorical BP was used in the other 6 trials to evaluate the efficacy of XZD.62–67 There were 321 patients in the XZD groups and 287 patients in the antihypertensive drugs groups, respectively. The categorical BP data were analyzed using a fixed-effects model according to the test of heterogeneity (chi-square = 6.05, \( P = 0.30 \), \( I^2 = 17\% \)). A significant decrease on BP was identified in favor of XZD therapy after treatment when compared with the antihypertensive drugs (RR = 1.32; 95% CI: 1.21 to 1.43, \( P < 0.00001 \)) (Fig. 2C).

Symptoms

Seven studies assessed the effectiveness of XZD on the symptoms outcomes in comparison with antihypertensive drugs.55–57,59,61,65,67 There were 349 patients in the XZD groups and 336 patients in the antihypertensive drugs groups. A fixed-effects model was applied based on the test of heterogeneity (chi-square = 8.90, \( P = 0.18 \), \( I^2 = 33\% \)). The meta-analysis identified a significant improvement on the symptoms outcomes by XZD therapy compared with antihypertensive drugs (RR = 1.26; 95% CI: 1.18–1.35, \( P < 0.00001 \)) (Fig. 3).

Blood Lipids

Four studies used the outcomes of lipid profile parameters to evaluate the effectiveness of XZD in hypertensive patients, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C).53,56,57,66 There were 146 patients in the XZD groups and 144 patients in the antihypertensive drugs groups. Pooled analysis demonstrated a significant lipid-lowering effects of XZD therapy on TC (\( n = 4; \) WMD = -1.47 mmol/L; 95% CI: -1.99 to -0.96, \( P < 0.00001 \); heterogeneity: chi-square = 12.71, \( P = 0.005 \), \( I^2 = 76\% \)), TG (\( n = 4; \) WMD = -1.04 mmol/L; 95% CI: -1.62 to -0.45, \( P = 0.0005 \); heterogeneity: chi-square = 14.31, \( P = 0.003 \), \( I^2 = 79\% \)), and LDL-C (\( n = 1; \) WMD = -0.60 mmol/L; 95% CI: -0.94 to -0.26, \( P = 0.0005 \); heterogeneity: not applicable), beyond HDL-C (\( n = 3; \) WMD = -0.14 mmol/L; 95% CI: -0.06 to 0.33, \( P = 0.17 \); heterogeneity: chi-square = 4.62, \( P = 0.10 \), \( I^2 = 57\% \)) when compared with the antihypertensive drugs (Fig. 4).

HCY

There was only 1 trial evaluating the effect of XZD with antihypertensive drugs alone on the outcome of serum HCY level.60 There were 52 patients in the XZD group and 51 patients in the antihypertensive drugs group. Pooled result was statistically significant in favor of XZD therapy (WMD = -5.90 μmol/
| References       | Sample Size (Randomized/ Analyzed) | Diagnostic Criteria | Intervention | Control | Treatment Duration | Adverse Events Report | Outcome Measures |
|------------------|-----------------------------------|---------------------|--------------|---------|--------------------|-----------------------|-------------------|
| Song and Wang 2010 | 70/70                             | WHO-ISH GMH-1999; GCRNDTCM | Modified XZD (1 dose/d) + C | Benazepril (10 mg, qd) | 12 weeks | N | SBP, DBP, TC, TG, HDL-C, and IMT |
| Li 2009          | 78/78                             | WHO-ISH GMH-1999; GCRNDTCM | Modified XZD (1 dose/d) + C | Hydrochlorothiazide (12.5 mg, bid) and 10% potassium chloride oral liquid (5 mg, bid) | 4 weeks | N | SBP and DBP |
| Wang and Qin 2008 | 122/122                            | WHO-ISH GMH-1999; TCM-SDC | Modified XZD (200 mL/d) + C | Hydrochlorothiazide (12.5 mg, bid) and 10% potassium chloride oral liquid (5 mg, bid) | 4 weeks | N | SBP, DBP, and symptoms |
| Chen 2014        | 60/60                             | CGMH-2010; GCRNDTCM | Modified XZD (1 dose/d) + C | Amlodipine (5–10 mg, qd) | 4 weeks | N | SBP, DBP, TC, TG, LDL-C, and symptoms |
| Wen 2011         | 60/60                             | GCRNDTCM | Modified XZD (1 dose/d) + C | Amlodipine besylate tablet (5–10 mg, qd) | 8 weeks | Y | SBP, DBP, TC, TG, HDL-C, symptoms, and hemorheology |
| Yang 2015        | 70/70                             | CGMH-2005; GCRNDTCM | Modified XZD (400 mL/d) + C | Enalapril maleate (10 mg, qd) and nifedipine (20 mg, bid) | 8 weeks | N | SBP, DBP, and LVMI |
| Hu 2014          | 128/128                            | WHO-ISH GMH-1999 | Modified XZD (100 mL/d) + C | Antihypertensive drugs (diuretic, angiotensin converting enzyme inhibitor, beta-blocker, calcium channel blocker, etc) | 8 weeks | Y | SBP, DBP, and symptoms |
| Li and Luo 2014   | 103/103                            | CGMH-2005 | XZD (200 mL/d) + C | Antiplatelet, atorvastatin calcium tablets, and antihypertensive drugs | 8 weeks | N | SBP, DBP and HCY |
| Wang 2011        | 70/65                             | CGMH-2005; GCRNDTCM | XZD (1 dose/d) + C | Fosinopril (10 mg, qd) | 4 weeks | Y | SBP, DBP, symptoms, and hemorheology |
| Liu 2014         | 90/90                             | CGMH-2005; GDTCIDCM-2008 | Modified XZD (450 mL/d) + C | Enalapril maleate (10 mg, bid) | 4 weeks | N | BP |
| Zhou et al 2014  | 60/60                             | WHO-ISH GMH-1999 | Modified XZD (1 dose/d) + C | Captopril (25 mg, bid) | 8 weeks | N | BP |
| Fu et al 2003    | 108/108                            | WHO-ISH GMH-1999 | Modified XZD (1 dose/d) + C | Nimodipine (30 mg, tid) | 8 weeks | N | BP |
Adverse Events

| Treatment Duration | Outcome Measures | Control | Intervention |
|--------------------|------------------|---------|--------------|
| N                  | BP and symptoms  | N       | Modified ZD (90 mL/d) + C | 128/128 |
| 4 weeks            | BP, TC, TG, and HDL-C | N       | MD (12.5 mg, tid) + C | 120/100 |
| 24 weeks           | BP and symptoms  | N       | Modified XZD (10 days) + C | 122/122 |
| 10 days            | BP and symptoms  | N       | Hydrochlorothiazide (50 mL/d) + C | 100/100 |

Sample Size (Randomized/Analysed)

- Liu 2014: 65 patients
- Guo 2013: 67 patients
- Liu 2001: 66 patients
- Zhao 2015: 65 patients

Diagnostic Criteria

- CGMH-2010: Chinese Guidelines for the Management of Hypertension
- WHO-ISH: World Health Organization Guidelines for the Management of Hypertension
- GMH-1999: Guidelines for the Management of Hypertension
- TCM-SDC: Traditional Chinese Medicine-Syndrome Differentiation Criteria
- CRNDTCM: Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine
- GDTCIDCM: Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine
- HCY: homocysteine
- HDL-C: high-density lipoprotein cholesterol
- LDL-C: low-density lipoprotein cholesterol
- LVMI: left ventricular mass index
- SBP: systolic blood pressure
- IMT: carotid intima-media thickness
- DBP: diastolic blood pressure
- TC: cholesterol
- TG: triglycerides
- Y: yes
- C: control group
- C0: no
- F0: 0%
- CI: confidence interval
- WMD: weighted mean difference
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: significance level
- CI: confidence interval
- P: signif...
| References         | T/C (M/F) | Age (yrs) | SBP (mm Hg) | DBP (mm Hg) | Baseline Difference |
|--------------------|-----------|-----------|-------------|-------------|---------------------|
| Song and Wang 2010 | T: 36 (21/15) C: 34 (20/14) | T: 48.11 ± 7.04 C: 48.07 ± 6.53 | T: 158.00 ± 16.00 C: 160.00 ± 15.00 | T: 95.00 ± 8.00 C: 96.00 ± 9.00 | NSD |
| Li 2009           | T: 39 (23/16) C: 39 (24/15) | T: 60 – 67 C: 61 – 68 | T: 159.98 ± 5.03 C: 161.03 ± 5.03 | T: 98.03 ± 2.03 C: 92.03 ± 3.00 | NSD |
| Wang and Qin 2008 | T: 64 (40/24) C: 58 (38/20) | T: 62.00 ± 3.00 C: 60.00 ± 2.00 | T: 132.00 ± 13.00 C: 133.00 ± 15.00 | T: 79.00 ± 7.00 C: 82.00 ± 7.00 | NSD |
| Chen 2014         | T: 30 (M/F: NR) C: 30 (M/F: NR) | T: 53.70 ± 13.24 C: 52.60 ± 13.40 | T: 137.18 ± 2.70 C: 151.95 ± 4.88 | T: 96.30 ± 8.92 C: 91.93 ± 6.59 | NSD |
| Wen 2011          | T: 37 (21/16) C: 33 (16/17) | T: 61 – 83 C: 62.10 ± 2.40 | T: 128.50 ± 8.60 C: 135.70 ± 8.80 | T: 84.60 ± 5.70 C: 92.20 ± 4.90 | NSD |
| Yang 2015         | T: 64 (30/34) C: 64 (46/18) | T: 63.40 ± 2.50 C: 62.10 ± 2.40 | T: 131.00 ± 26.00 C: 135.70 ± 8.80 | T: 93.40 ± 8.92 C: 81.93 ± 6.59 | NSD |
| Hu 2014           | T: 52 (M/F: NR) C: 51 (M/F: NR) | T: 60 – 76 C: 62.10 ± 2.40 | T: 128.50 ± 8.60 C: 135.70 ± 8.80 | T: 84.60 ± 5.70 C: 92.20 ± 4.90 | NSD |
| Wang 2011         | T: 33 (19/14) C: 32 (18/14) | T: 53.13 ± 9.64 C: 52.43 ± 9.07 | T: 131.72 ± 10.24 C: 136.38 ± 9.64 | T: 93.40 ± 8.92 C: 81.93 ± 6.59 | NSD |
| Liu 2014          | T: 45 (24/21) C: 45 (25/20) | T: 33 – 71 C: 31 – 74 | T: 128.50 ± 8.60 C: 135.70 ± 8.80 | T: 93.40 ± 8.92 C: 81.93 ± 6.59 | NSD |
| Zhou et al 2014   | T: 30 (M/F: NR) C: 30 (M/F: NR) | T: 39 – 78 C: 38 – 82 | T: 131.72 ± 10.24 C: 136.38 ± 9.64 | T: 93.40 ± 8.92 C: 81.93 ± 6.59 | NSD |
| Fu et al 2003     | T: 68 (M/F: NR) C: 40 (M/F: NR) | T: 67.40 ± 4.90 C: 67.20 ± 5.10 | T: 128.50 ± 8.60 C: 135.70 ± 8.80 | T: 93.40 ± 8.92 C: 81.93 ± 6.59 | NSD |
| Liu 2014          | T: 64 (37/27) C: 64 (36/28) | T: 36 – 58 C: 40 – 60 | T: 131.72 ± 10.24 C: 136.38 ± 9.64 | T: 93.40 ± 8.92 C: 81.93 ± 6.59 | NSD |
| Lu 2001           | T: 50 (30/20) C: 50 (25/25) | T: 62.00 ± 3.00 C: 60.00 ± 2.00 | T: 131.72 ± 10.24 C: 136.38 ± 9.64 | T: 93.40 ± 8.92 C: 81.93 ± 6.59 | NSD |
| Guo 2013          | T: 64 (40/24) C: 58 (38/20) | T: 62.00 ± 3.00 C: 60.00 ± 2.00 | T: 131.72 ± 10.24 C: 136.38 ± 9.64 | T: 93.40 ± 8.92 C: 81.93 ± 6.59 | NSD |

AT = after treatment, BT = before treatment, C = control group, DBP = diastolic blood pressure, F = female, M = male, NR = no reported, NSD = no significant difference, SBP = systolic blood pressure, T = treatment group.
| References          | CHM            | Components                                                                 |
|---------------------|----------------|-----------------------------------------------------------------------------|
| Song and Wang 2010  | Modified XZD   | Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 10 g, Peach Kernel (Taoren, Persicae Semen) 10 g, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 10 g, Red Peony Root (Chishao, Radix Rubr) 10 g, Orange Fruit (Zhike, Fructus Aurantii) 10 g, Root of the Balloon Flower (Jiegeng, Platycladi Radix) 10 g, Rehmanna (Di Huang, Radix Rehmanniae Glutinosae) 10 g, Abalone Shell (Shi Jue Ming, Halotitis Concha) 10 g, Gambir Vine Stems and Thorns (Gouteng, Ramulus Uncariae cum Unci) 10 g, Safflower Flower (Honghua, Flos Carthami Tinctorii) 5 g, Liquorice Root (Gan Cao, Radix Glycyrrhizae) 5 g, Achyranthes Root (Niu Xi, Achyranthis Bidentatae Radix) 20 g, Crataegus Fruit (Shan Zha, Crataegi Fructus) 20 g, Five leaf Gynostemma Herb (Jiaogulan, Gynostemma Pentaphyllo. Thumb) 20 g, Thorowax Root (Chaihu, Radix Bupleuri) 15 g, and Baical Skullcap Root (Huang Qin, Radix Scutellariae Baicalensis) 30 g. |
| Li 2009             | Modified XZD   | Peach Kernel (Taoren, Persicae Semen) 10 g, Safflower Flower (Honghua, Flos Carthami Tinctorii) 9 g, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 9 g, Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 15 g, Red Peony Root (Chishao, Radix Rubrus Paeoniae Lactiflorae) 20 g, Rehmanna (Shengdihuang, Radix Rehmanniae Glutinosae) 24 g, Rehmanna (Shu di huang, Radix Rehmanniae Glutinosae) 24 g, Thorowax Root (Chaihu, Radix Bupleuri) 12 g, Orange Fruit (Zhike, Fructus Aurantii) 12 g, Achyranthes Root (Niu Xi, Achyranthis Bidentatae Radix) 15 g, Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematea) 12 g, Pueraria (Gegen, Radix Puerariae) 25 g, Chrysanthemum Flower (Juhua, Flos Chrysanthemi Morifolii) 10 g, Foetid Cassia Seeds (Juemingzi, Semen Cassiae Torae) 12 g, Chicken Gizzard’s Internal Lining (Ji Nei Jin, Endothelium Comeum Gigeriae Galli) 12 g, Cnataegus Fruit (Shan Zha, Cnataegi Fructus) 3 g, Salvia Root (Dan Shen, Radix Salviae Miltiorrhizae) 3 g, and Prunella (Xiakucao, Spica Prunellae Vulgaris) 3 g. If shortness of breath and hypodynama were identified, Astragalus (Huangqi, Radix Astragali Membranaceae) was added. If qi stagnation was identified, Nut Grass Rhizome (Xiang fu, Rhizoma Cyperi Rotundi) and Cordyceps Rhizome (Yanhusuo, Cordyceps Rhizome) were added. If anorexia and abdominal distension were identified, Rice Sprout (Gaya, Fructus Germinatus Oryzae Sativae), Barley Sprout (Maiya, Fructus Germinatus Hordei Vulgaris), Medicated Leaven (Shen Qu, Massa Medicata Fermentata), Amomum Fruit (Sharen, Amomi Semen seu Fructus), Magnolia Bark (Houpu, Cortex Magnoliae Officinalis), and Costus Root (Muxiang, Radix Aucklandiae Lappae) were added. If phlegm dampness was identified, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae), Poria (Fuling, Scierotium Poriae Cosos), and White Atractylodes Rhizome (Baizhu, Rhizoma Atractylodis Macrocephalae) were added. If turbid phlegm was identified, Acorus Root (Shi Chang Pu, Acori Rhizoma) and Ariesaematis Root (Tian Nan Xing, Arisaematis Rhizoma) were added. If thirst was identified, Trichosanthes Root (Tianhualen, Trichosanthis Radix) and Ophiopogon (Maidong, Tuber Ophiopogonis Japonici) were added. If constipation was identified, Rhabar Root and Rhizome (Da huang, Radix Et Rhizoma Rhei) was added. If yin deficiency and fire hyperactivity was identified, Privet Fruit (Nvzhenzi, Fructus Ligustri Lucidi) and Eclipta (Mo han lian, Herba Ecliptae Prostratae) were added. If insomnia was identified, Flowe Knotweed Stem (Shou Wu Teng, Polygoni Multiflori Caulis), Mimosa Tree Bark (He huan pi, Cortex Albizziae Julibrissini), and Chinese Senega Root (Yuan zhi, Radix Polygalae Tenuifoliae) were added. |
| Wang and Qin 2008   | Modified XZD   | Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 10 g, Rehmanna (Di huang, Radix Rehmanniae Glutinosae) 10 g, Peach Kernel (Taoren, Persicae Semen) 10 g, Safflower Flower (Honghua, Flos Carthami Tinctorii) 10 g, Orange Fruit (Zhike, Fructus Aurantii) 3 g, Achyranthes Root (Niu xi, Achyranthis Bidentatae Radix) 12 g, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 10 g, Salvia Root (Dan Shen, Radix Salviae Miltiorrhizae) 20 g, Earthworm (Dilong, Lumbricus) 30 g, Eucommia Bark (Du Zhong, Cortex Eucommiae Ulmoidis) 12 g, Chinese Taxillus Twig (Sang Ji Sheng, Herba Taxilli) 15 g, and Liquorice Root (Gan Cao, Radix Glycyrrhizae) 6 g. |
| References | CHM | Components |
|------------|-----|------------|
| Chen 2014  | Modified XZD | Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 10 g, Rehmannia (Di huang, Radix Rehmanniae Glutinosae) 20 g, Peach Kernel (Taoren, Persicae Semen) 12 g, Safflower Flower (Honghua, Flos Carthami Tinctoria) 10 g, Orange Fruit (Zhike, Fructus Aurantii) 12 g, Red Peony Root (Chi Shao, Radix Rubrae Paeoniae Lactiflorae) 15 g, Thorowax Root (Chaihu, Radix Bupleuri) 15 g, Liquorice Root (Gan Cao, Radix Glycyrrhizae) 12 g, Root of the Balloon Flower (Jiegeng, Platycodi Radix) 12 g, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 6 g, and Achyranthes Root (Niu Xi, Achyranthis Bidentatae Radix) 15 g. If liver fire was identified, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) and Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) were removed, and Prunella (Xiakucao, Spica Prunellae Vulgaris) 10 g, Gardenia (Zhi Zi, Fructus Gardeniae Jasminoidis) 10 g, and Gambir Vine Stems and Thorns (Gouteng, Ramulus Uncariae Cum Uncis) 15 g were added. If yin deficiency was identified, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) and Thorowax Root (Chaihu, Radix Bupleuri) were removed, and Mother of Pearl (Zhen Zhu Mu, Concha Margaritiferae) 30 g, Chrysanthemum Flower (Juhua, Flos Chrysanthemi Morifolii) 15 g, and Chinese Wolfberry Fruit (Gouqizi, Fructus Lycii Chinensis) 15 g were added. If qi deficiency was identified, Codonopsis Root (Dang Shen, Radix Codonopsis Pilosulae) 15 g and Eucommia Bark (Du Zhong, Cortex Eucommiae Ulmoidis) 15 g were added. If phlegm dampness was identified, Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) was removed, and Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 10 g, Arisaema Root (Tian Nan Xing, Arisaematis Rhizoma) 10 g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 10 g, and Portia (Fuling, Scierotium Portiae Cocos) 20 g were added. If palpitation was identified, Salvia Root (Dan Shen, Radix Angelicae Sinensis) 10 g, Salvia Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 10 g, Orange Fruit (Zhike, Fructus Aurantii) 12 g, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 10 g, Peach Kernel (Taoren, Persicae Semen) 6 g, Safflower Flower (Honghua, Flos Carthami Tinctoria) 6 g, Root of the Balloon Flower (Jiegeng, Platycodi Radix) 6 g, and Orange Fruit (Zhike, Fructus Aurantii) 6 g. If palpitation was identified, Salvia Root (Dan Shen, Radix Salviae Miltiorrhizeae) and Tumeric Tuber (Yu Jin, Tuber Curcumae) were added. If turbid phlegm was identified, Arisaema Root (Tian Nan Xing, Arisaematis Rhizoma) and Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 12 g, and Liquorice Root (Gan Cao, Radix Glycyrrhizae) 6 g. If palpitation was identified, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae), Portia (Fuling, Scierotium Portiae Cocos), and White Atractylodes Rhizome (Baizhu, Rhizoma Atractylodis Macrocephalae) were added. If insomnia was identified, Flowey Knotweed Stem (Shou Wu Teng, Polygoni Multiflori Caulis), Mimosa Tree Bark (He Huan Pi, Cortex Albizziae Julibrissinis), and Chinese Senega Root (Yuan Zhi, Radix Polygalae Tenuifoliae) were added. If shortness of breath and hypodynamia were identified, Astragalus (Huangqi, Radix Astragali Membranacei) were added. If insomnia was identified, Flowey Knotweed Stem (Shou Wu Teng, Polygoni Multiflori Caulis), Mimosa Tree Bark (He Huan Pi, Cortex Albizziae Julibrissinis), and Chinese Senega Root (Yuan Zhi, Radix Polygalae Tenuifoliae) were added. |
References | CHM | Components
--- | --- | ---
Li and Luo 2014 | XZD | Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 9 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 9 g, Rehmannia (Di Huang, Radix Rehmanniae Glutinosae) 9 g, Safflower Flower (Honghua, Flos Carthami Tintorii) 9 g, Peach Kernel (Taoren, Persicae Semen) 12 g, Orange Fruit (Zhike, Fructus Aurantii) 6 g, Liquorice Root (Gancao, Radix Glycyrrhizae) 6 g, Red Peony Root (Chishao, Radix Rubruses Paeoniae Lactiflorae) 6 g, Thorowax Root (Chaihu, Radix Bupleuri) 3 g, Root of the Balloon Flower (Jiegeng, Platycodi Radix) 4.5 g, and Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 4.5 g.

Wang 2011 | XZD | Peach Kernel (Taoren, Persicae Semen) 20 g, Safflower Flower (Honghua, Flos Carthami Tintorii) 15 g, Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 15 g, Rehmannia (Di Huang, Radix Rehmanniae Glutinosae) 15 g, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 7.5 g, Red Peony Root (Chishao, Radix Rubruses Paeoniae Lactiflorae) 10 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 15 g, Root of the Balloon Flower (Jiegeng, Platycodi Radix) 7.5 g, Thorowax Root (Chaihu, Radix Bupleuri) 5 g, Orange Fruit (Zhike, Fructus Aurantii) 10 g, and Liquorice Root (Gancao, Radix Glycyrrhizae) 5 g.

Liu 2014 | Modified XZD | Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 15 g, Rehmannia (Di Huang, Radix Rehmanniae Glutinosae) 15 g, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 10 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 15 g, Peach Kernel (Taoren, Persicae Semen) 15 g, Ass Hide Glue (Ejiao, Gelatinum Corii Asini) 10 g, White Peony Root (Bai Shao, Radix Albus Paeoniae Lactiflorae) 10 g, Safflower Flower (Honghua, Flos Carthami Tintorii) 15 g, Thorowax Root (Chaihu, Radix Bupleuri) 5 g, Orange Fruit (Zhike, Fructus Aurantii) 11 g, Root of the Balloon Flower (Jiegeng, Platycodi Radix) 10 g, and Liquorice Root (Gancao, Radix Glycyrrhizae) 10 g. If constipation was identified, Rhus왁 Root and Rhizome (Da Huang, Radix Et Rhizoma Rhei) 12 g, and Sodium Sulfate Powder (Mangxiao, Natrii Sulfas Exsiccatas) 3 g were added. If headache and dizziness were identified, Abalone Shell (Shi Jue Ming, Haliotidis Concha) 20 g and Gastrodia (Tianma, Gastrodiae Rhizoma) 12 g were added. If tinnitus and insomnia were identified, Circula Moutiling (Chantui, Periostracum Cicadae) 15 g and Spiny Jujube Kernel (Suanzaoren, Ziziphi Spinosi Semen) 20 g were added.

Zhou et al 2014 | Modified XZD | Astragalus (Huangqi, Radix Astragali Membranaceae) 25 g, Peach Kernel (Taoren, Persicae Semen) 9 g, Safflower Flower (Honghua, Flos Carthami Tintorii) 5 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 10 g, Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 10 g, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 10 g, Thorowax Root (Chaihu, Radix Bupleuri) 8 g, Red Peony Root (Chishao, Radix Rubruses Paeoniae Lactiflorae) 15 g, Rehmannia (Di Huang, Radix Rehmanniae Glutinosae) 15 g, Orange Fruit (Zhike, Fructus Aurantii) 12 g, Salvia Root (Dan Shen, Radix Salviae Miltiorrhizae) 30 g, and Crataegus Fruit (Shan Zha, Crataegi Fructus) 30 g.

Fu et al 2003 | Modified XZD | Peach Kernel (Taoren, Persicae Semen) 9 g, Achyranthes Root (Niuxi, Achyranthis Bidentatae Radix) 9 g, Chinese Angelica Root (Danggui, Radix Angelicae Sinensis) 12 g, Szechuan Lovage Root (Chuanxiong, Rhizoma Ligustici Chuanxiong) 12 g, Thorowax Root (Chaihu, Radix Bupleuri) 12 g, White Peony Root (Bai Shao, Radix Albus Paeoniae Lactiflorae) 20 g, Rehmannia (Di Huang, Radix Rehmanniae Glutinosae) 20 g, Orange Fruit (Zhike, Fructus Aurantii) 15 g, Vitex Fruit (Manjingzi, Fructus Vitici) 15 g, Salvia Root (Dan Shen, Radix Salviae Miltiorrhizae) 30 g, Prunella (Xiakucao, Spica Prunellae Vulgaris) 30 g, and Crataegus Fruit (Shan Zha, Crataegi Fructus) 30 g. If liver fire was identified, Chinese Gentian Root (Longdancao, Radix Gentianae Longdancao) 10 g, Orange Fruit (Zhike, Fructus Aurantii) 12 g, Gardenia (Zhizi, Fructus Gardeniae Jasminoidis) 10 g, and Rehmannia (Di Huang, Radix Rehmanniae Glutinosae) 20 g. If yang deficiency with yang hyperactivity was identified, Mother of Pearl (Zhen Zhu Mu, Concha Margaritifera) 30 g, Chrysanthemum Flower (Juhua, Flos Chrysanthemi Monofolii) 15 g, and Chinese Wolfberry Fruit (Gouqizhi, Fructus Lycii Chinensis) 15 g were added. If yang deficiency was identified, Codonopsis Root (Dang Shen, Radix Codonosipis Pilosulae) 15 g and Aerial Parts of Epimedium (Yin Yang Huo, Herba Epimedii) 10 g were added. If phlegm-fire was identified, Pinellia Rhizome (Banxia, Rhizoma Pinelliae Tematae) 10 g, Arisaema Root (Tian Nan Xing, Arisaematis Rhizoma) 10 g, Tangerine Peel (Chenpi, Pericarpium Citri Reticulatae) 10 g, and Poria (Fuling, Scierotium Poriae Cocos) 15 g were added.
Xuefu Zhuyu Decoction for Hypertension

**DISCUSSION**

**Summary of Evidences**

Currently, there were clinical evidence ranged from case studies, case series, controlled trials to RCTs showing that XZD is effective in treating hypertensive patients; however, no high level of evidence such as systematic review or meta-analysis was provided for further recommendation. The purpose of this systematic review was to summarize the potential cardiovascular protective actions of XZD in patients with hypertension.

A total of 15 claimed RCTs involving 1364 hypertensive patients met the inclusion criteria in this review. In general, the pooled analyses of the current RCTs demonstrated a superior therapeutic effect of XZD as adjuvant therapy in treating hypertension. That is, XPAD is more effective in lowering SBP and DBP than antihypertensive therapy alone.

The main therapeutic goal of treating hypertension are to not only reduce BP to the normal level, but also reverse cardiovascular risk factors, protect the target organs, and reduce mortality and cardiovascular events. This is a systematic review and meta-analysis on the potential role of XZD for hypertension. There were several strengths in this review. First, antihypertensive therapy is the cornerstone of hypertension treatment. On the basis of the guidelines on hypertension by the Eighth Joint National Committee, goal BP was <90 mm Hg in hypertensive persons 30 to 59 years and goal <150/90 mm Hg in hypertensive persons age ≥60 years, and goal DBP <90 mm Hg in hypertensive persons 30 to 59 years. Evidence also indicates that hypertensive patients could benefit from antihypertensive therapy when reaching the recommended threshold BP values. In our review, 9 trials (9/15, 60%) reported the outcomes on BP values and meta-analysis by subgroup showed that in hypertensive patients treated by XZD, the mean additional reduction in SBP was 6.99 mm Hg and DBP was 4.44 mm Hg. In the other 6 trials (6/15, 40%), the results also

**TABLE 4. Methodologic Quality of the Included Trials Based on the Cochrane Handbook**

| References | A | B | C | D | E | F | G | H |
|------------|---|---|---|---|---|---|---|---|
| Song and Wang 2010 | 65 | ? | ? | ? | ? | ? | + | ? |
| Li 2009 | 64 | ? | ? | ? | ? | ? | + | ? |
| Wang and Qin 2008 | 63 | ? | ? | ? | ? | ? | + | ? |
| Chen 2014 | 62 | ? | ? | ? | ? | ? | + | ? |
| Wen 2011 | 61 | ? | ? | ? | ? | ? | + | ? |
| Yang 2015 | 60 | ? | ? | ? | ? | ? | + | ? |
| Hu 2014 | 59 | ? | ? | ? | ? | ? | + | ? |
| Li and Luo 2014 | 58 | ? | ? | ? | ? | ? | + | ? |
| Wang 2011 | 57 | + | ? | ? | ? | ? | + | ? |
| Liu 2014 | 56 | + | ? | ? | ? | ? | + | ? |
| Zhou et al 2014 | 55 | ? | ? | ? | ? | ? | + | ? |
| Fu et al 2003 | 54 | ? | ? | ? | ? | ? | + | ? |
| Liu 2014 | 53 | + | ? | ? | ? | ? | + | ? |
| Lu 2001 | 52 | ? | ? | ? | ? | ? | + | ? |
| Guo 2013 | 51 | + | ? | ? | ? | ? | + | ? |

A = adequate sequence generation, B = concealment of allocation, C = blinding (patient), D = blinding (investigator), E = blinding (assessor), F = incomplete outcome data addressed (ITT analysis), G = free of selective reporting, H = other potential threat to validity; +, low risk; -, high risk; ?, unclear.
showed statistical significance compared with antihypertensive drugs alone. Our systematic review and meta-analysis was consistent with some prior reviews supporting use of traditional Chinese herbal formulae therapy for hypertension.72–74

Second, in some cases, the hypertension-related symptoms seriously troubled patients, although the elevated BP has been effectively controlled.75 According to the evaluation criterion in GCRNDTCM, these symptoms included headache, dizziness, insomnia, irritability, etc. We investigated the efficacy of XZD on the common symptoms in patients with hypertension in this study. Seven trials (7/15, 46.67%) were identified and the subgroup meta-analysis supported that XZD significantly improved symptoms in patients with hypertension; however, we should pay attention to that, an accurate TCM syndrome

FIGURE 2. Forest plot of the comparison of XZD versus antihypertensive drugs for the outcome of BP. A, SBP; B, DBP; and C, categorical BP. BP = blood pressure, DBP = diastolic blood pressure, SBP = systolic blood pressure, XZD = xuefu zhuyu decoction.

FIGURE 3. Forest plot of the comparison of XZD versus antihypertensive drugs for the outcome of symptoms. XZD = xuefu zhuyu decoction.
diagnosis is formed based on the collected symptoms and signs of the patients. Only 10 studies (10/15, 66.67%) reported the use of diagnostic criteria of TCM syndrome. As we know, a better therapeutic benefit might be achieved when the prescribed Chinese herbal medicine fit the TCM syndrome diagnosis. Therefore, we suggested that the theory of formula corresponding to syndrome in TCM should be reunderstood either in theory or in practice; and that both using and reporting the TCM syndrome diagnosis should be considered in further researches.

Third, the treatment goal of hypertension also includes managing the coexistent risk factors for cardiovascular disease together. The efficacy of XZD on blood lipids was evaluated in this study. A significant improvement on blood lipids was identified, with TC, TG LDL-C, and decreased by 1.47, 1.04, and 0.60 mmol/L, respectively. A clinically, but not statistically, significant increase in HDL-C was also observed by XZD therapy. HCY is regarded as a risk factor for hypertension and plays an important role in the development and progression of carotid atherosclerosis in hypertensive patients. Epidemiologic survey confirmed that high HCY level might increase the risk of hypertension. In this review, XZD significantly lowered the serum HCY level in hypertensive patients. Additionally, the hemorheology is an important biochemical index for diagnosing blood stasis syndrome and evaluating the therapeutic effects of PBCRBS-based herb and formulae in TCM. In our review, the hemorheology was significantly improved by XZD treatment comparing with the antihypertensive drugs alone. The results were consistent with previous meta-analysis of PBCRBS-based formulae on the

![Figure 4](image-url)  
**FIGURE 4.** Forest plot of the comparison of XZD versus antihypertensive drugs for the outcome of blood lipids. A, TC; B, TG; C, HDL-C; and D, LDL-C. HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TC = total cholesterol, TG = triglycerides, XZD = xuefu zhuyu decoction.

![Figure 5](image-url)  
**FIGURE 5.** Forest plot of the comparison of XZD versus antihypertensive drugs for the outcome of HCY. HCY = homocysteine, XZD = xuefu zhuyu decoction.
outcomes of hemorheology. As only few studies provided data for blood lipids, HCY, and hemorheology, more clinical evidence are warranted to confirm the conclusions.

Fourth, an interesting finding of this review is the evaluation of XZD on target organ damage (TOD) in hypertensive patients. Long-term high BP induces vasculature, myocardium, and renal remodeling. Left ventricular hypertrophy, impaired renal function, and albuminuria are manifestations of TOD in hypertension, all of which are considered strong predictors for cardiovascular events and mortality. Therefore, current

FIGURE 6. Forest plot of the comparison of XZD versus antihypertensive drugs for the outcome of hemorheology. A, high shear blood viscosity; B, moderate shear blood viscosity; C, low shear blood viscosity; D, plasma viscosity; E, hematocrit; and F, fibrinogen. XZD = xuefu zhuyu decoction.

FIGURE 7. Forest plot of the comparison of XZD versus antihypertensive drugs for the outcome of IMT. IMT = carotid intima-media thickness, XZD = xuefu zhuyu decoction.
guidelines for the management of hypertension recommend that the preliminary evaluation of cardiovascular risks in hypertensive patient should focus on not only BP levels, but also TOD by measuring renal function, albuminuria, left ventricular hypertrophy, IMT, and pulse wave velocity. The effects of XZD on TOD were assessed in this systematic review and meta-analysis. A significant improvement on IMT and LVMI was identified in the XZD group compared with antihypertensive drugs alone.

Additionally, XZD treatment was well tolerated in the enrolled patients. No severe adverse events occurred in the XZD groups compared with the antihypertensive drugs groups. This systematic review suggested that XZD might be a safe TCM approach in managing hypertension; however, as only 3 trials reported the adverse events, it is still difficult to draw any definite conclusion.

**LIMITATIONS**

Before accepting the above positive findings, the following limitations should also be considered. First, although comprehensive literature search was conducted in the 7 electronic databases, databases published in other languages except Chinese and English were not included in our study. Thus, a certain degree of potential selective bias might exist and some relevant publications of XZD might be missed.

Second, Vickers et al. have pointed out that only positive results were produced in some countries. In our review, all of the 15 included studies were conducted in China and published in Chinese. Moreover, positive results were reported in most of the included studies and some negative results could not be reported. We understood that negative results were often difficult to be accepted in most Chinese journals currently. Thus, the efficacy of XZD for hypertension might be overestimated. Similar questions were also confronted in the previous published systematic reviews of Chinese herbal medicine.

Third, we rigorously assessed the methodologic quality of the included trials based on the Cochrane Collaboration’s tool. The methodologic quality is poor, which is the inherent shortcomings in primary studies. For example, all the included studies declared that, participants were randomized into the XZD group and antihypertensive drugs group; however, only 5 trials provided the adequate sequence generation and no trials reported the concealment of allocation. Inadequate reporting and poor methodologic design might weaken the strength and credibility of the clinical evidence of XZD in this review.

**CONCLUSION**

In summary, XZD could improve BP, symptoms, blood lipids, HCY, hemorheology, IMT, and LVMI in hypertensive patients. Although some limitations such as potential selective bias and methodologic flaws might undermine the validity of positive findings, XZD is beneficial for hypertension treatment. From a clinical point of view, further RCTs with high-quality and long-term follow-up are recommended to generate high level of clinical evidence. Altogether, this systematic review and meta-analysis here provides an evidence-based approach to the management of hypertension and suggests XZD as a new candidate cardioprotective drug, which should be given priority for future preclinical and clinical studies.

**REFERENCES**

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *J Am Med Assoc.* 2003;289:2560–2572.
2. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. *J Am Coll Cardiol.* 2015;65:1998–2038.
3. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *J Am Med Assoc.* 2014;311:507–520.
4. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223.

5. Egan BM, Li J, Hutchison FN, et al. Hypertension in the United States, 1999 to 2012: progress toward healthy people 2020 goals. Circulation. 2014;130:1692–1699.

6. Egan BM, Li J, Shatat IF, et al. Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010. Circulation. 2014;129:2052–2061.

7. Sever PS, Dahlbøf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003;361:1149–1158.

8. Kushi T, Mizuno K, Nakaya N, et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension. 2009;53:135–141.

9. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381:1987–2015.

10. Jiang B, Hongmei L, Xiaojuan R, et al. Hypertension detection, management, control and associated factors among residents accessing community health services in Beijing. Sci Rep. 2014;4:e4845.

11. Mansoor GA. Herbs and alternative therapies in the hypertension clinic. Am J Hypertens. 2001;14:971–975.

12. Xiong XJ, Yang XC, Liu YM, et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertens Res. 2013;36:570–579.

13. Brook RD, Jackson EA, Giorgini P, et al. When and how to recommend ‘alternative approaches’ in the management of high blood pressure. Am J Med. 2015;128:567–570.

14. Xiong XJ. Integrating traditional Chinese medicine into Western cardiovascular medicine: an evidence-based approach. Nat Rev Cardiol. 2015;12:e374.

15. Brook RD, Appel LJ, Rubenfire M, et al. on behalf of the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity and Metabolism. Beyond medications and diet: alternative approaches to lowering blood pressure. Hypertension. 2013;61:1360–1383.

16. Vogel JH, Bolling SF, Costello RB, et al. Integrating complementary medicine into cardiovascular medicine. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine). J Am Coll Cardiol. 2005;46:184–221.

17. Xiong XJ, Wang PQ, Li XK, et al. Qigong for hypertension: a systematic review. Medicine. 2015;94:e4352.

18. Wang J, Feng B, Yang XC, et al. Tai Chi for essential hypertension. Evid Based Complement Alternat Med. 2013;2013:e215254.

19. Xiong XJ, Wang PQ, Li SJ, et al. Effect of Badanjin exercise for hypertension: a systematic review and meta-analysis of randomized controlled trials. Maturitas. 2015;80:370–378.

20. Cramer H, Lauche R, Haller H, et al. Effects of yoga on cardiovascular disease risk factors: a systematic review and meta-analysis. Int J Cardiol. 2014;173:170–183.

21. Xiong XJ, Li SJ, Zhang YQ. Massage therapy for essential hypertension: a systematic review. J Hum Hypertens. 2015;29:143–151.

22. Flachskampf FA, Gallasch J, Gefeller O, et al. Randomized trial of acupuncture to lower blood pressure. Circulation. 2007;115:3121–3129.

23. Xiong XJ, Liu W, Yang XC, et al. Moxibustion for essential hypertension. Complement Ther Med. 2014;22:187–195.

24. Lee MS, Choi TY, Shin BC, et al. Cupping for hypertension: a systematic review. Clin Exp Hypertens. 2010;32:423–425.

25. Xiong XJ, Wang PQ, Li SJ, et al. Garlic for hypertension: a systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2015;32:352–361.

26. Xiong XJ, Li XK, Zhang YQ, et al. Chinese herbal medicine for resistant hypertension: a systematic review. BMJ Open. 2015;5:e005355.

27. Xiong XJ, Yang XC, Liu W, et al. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine. Evid Based Complement Alternat Med. 2013;2013:275279.

28. Wang J, Xiong XJ. Evidence-based Chinese medicine for hypertension. Evid Based Complement Alternat Med. 2013;2013:978398.

29. Goto H. Blood stasis syndrome in Japan and its molecular biological analysis. Chin J Integr Med. 2014;20:490–495.

30. Xiong XJ, Wang Z, Wang J. Innovative strategy in treating angina pectoris with Chinese patent medicines by promoting blood circulation and removing blood stasis: experience from combination therapy in Chinese medicine. Curr Vasc Pharmacol. 2015;13:540–553.

31. You S, Park B, Lee MS. Accelerated RBC senescence as a novel pathologic mechanism of blood stasis syndrome in traditional East Asian medicine. Am J Transl Res. 2015;7:422–429.

32. Yu TT. Treatment for hypertension according to blood stasis syndrome. World Chin Med. 2013;8:1172–1176.

33. Wang MM, Fang MX, Chen LG, et al. Differential expression of microRNA in endothelial cells incubated with serum of hypertension patients with blood-stasis syndrome. Chin J Integr Med. 2015;In press. http://link.springer.com/article/10.1007%2Fs11655-015-2053-1.

34. Xiong XJ, Wang PQ, Li XK, et al. Effects of traditional Chinese patent medicine on essential hypertension: a systematic review. Medicine. 2015;94:e442.

35. Wang J, Yang XC, Feng B, et al. Is Yangxue Qingnao Granule combined with antihypertensive drugs, a new integrative medicine therapy, more effective than antihypertensive therapy alone in treating essential hypertension? Evid Based Complement Alternat Med. 2013;2013:540613.

36. Xiong XJ, Liu W, Yang XC, et al. Ginkgo biloba extract for essential hypertension: a systematic review. Phytomedicine. 2014;21:1131–1136.

37. Shoja MM, Tubbs RS, Shokouhi G, et al. Wang Qingren and the 19th century Chinese doctrine of the bloodless heart. Int J Cardiol. 2010;145:305–306.

38. Huang Q, Qiao X, Xu X. Potential synergism and inhibitors to multiple target enzymes of Xuefu Zhuyu Decoction in cardiac disease therapeutics: a computational approach. Bioorg Med Chem Lett. 2007;17:1779–1783.

39. Yi GZ, Qiu YQ, Xiao Y, et al. The usefulness of xuefu zhuyou tang for patients with angina pectoris: a meta-analysis and systematic review. Evid Based Complement Alternat Med. 2014;2014:521602.

40. Luo J, Xu H, Yang G, et al. Oral Chinese proprietary medicine for angina pectoris: an overview of systematic reviews/meta-analyses. Complement Ther Med. 2014;22:787–800.

41. Ding YW, Xu Y. Clinical study of Xuefu Zhuyou Decoction on 151 cases of hypertension. New Chin Med. 2001;33:38–39.
42. Zhang L, Zhu L, Wang Y, et al. Characterization and quantification of major constituents of Xue Fu Zhu Yu by UPLC-DAD-MS/MS. J Pharm Biomed Anal. 2012;62:203–209.
43. Zhang GH, Lv L. Effect of Tianma gouteng yin, Wendan tang and Xuefu zhuyu tang on ALDO and AngII level in myocardial tissue and plasma of spontaneous hypertensive rats. Shandong Med J. 2012;52:11–13.
44. Wu WH, Ji ZQ, Ji WY. Effect of the new Xuefu zhuyu tang on endothelial function and prethrombotic state in hypertensive rats. Chin J Integr Med Cardio-cerebrovasc Dis. 2007;5:1084–1085.
45. Zhang SL, Ji ZQ, Ji WY. Effect of modified Xuefu zhuyu decoction on vascular remodeling in hypertensive rat. Med J Qilu. 2012;27:136–138.
46. Wan XH, Deng LZ, Tang Y, et al. Effect of Xuefuzhuyutang in carotid artery vascular remodeling in spontaneous hypertensive rats. Chin J Arteriosclerosis. 2004;12:402–404.
47. Ji ZQ, Wu WH, Ji WH. Mechanism study of the impacts on myocardial fibrosis treated with modified Xuefu Zhuyu Decoction in the rats with hypertension. World J Integr Tradit West Med. 2004;6:385–388.
48. Zhang GH, Yang G, Zhao XL. Effect of Xuefu zhuyu tang, Tianma gouteng yin and Wendan tang on the MAPK signaling pathway in myocardial tissue of spontaneously hypertensive rats. Shandong Med J. 2014;54:28–30.
49. Zhang GH. Effect of Xuefu zhuyu tang, Wendan tang and Tianma gouteng yin on the expression of TNF-α, IFN-γ, G-CSF and MCP-1 in myocardial tissue of spontaneously hypertensive rats. Shandong Med J. 2013;53:26–28.
50. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
51. Xiong XJ, Wang PQ, Li XK, et al. The effect of Chinese herbal medicine Jia Jeng Decoction for the treatment of essential hypertension: a systematic review. BMJ Open. 2015;5:e006502.
52. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org/. Accessed at July 17, 2015.
53. Song QL, Wang J. Clinical observation on the effect of Xuefu Zhuyu Decoction for the treatment of 36 cases of hypertensive patients with blood stasis syndrome. J New Chin Med. 2010;42:8–9.
54. Li YQ. The application of modified Xuefu Zhuyu Decoction for the treatment of senile hypertension. Chin Med Mod Dist Educ Chin. 2009;7:89–90.
55. Wang M, Qin Y. Observation on the effect of Xuefu Zhuyu Decoction on 64 hypertension patients. Chin Trop Med. 2008;8:1564–1565.
56. Chen XX. Clinical study of Xuefu Zhuyu Decoction combined with amiodipine in treating blood stasis type hypertension. Chin J Pr Med. 2014;41:59–61.
57. Wen W. Clinical Research on the Effect of Modified Xuefu Zhuyu Decoction Combined With Amiodipine Beseylate Tablets in Treating Hypertension With Blood Stasis Syndrome. Guangzhou University of Chinese Medicine; 2011:1–38.
58. Yang Y. Effect of modified Xuefu Zhuyu Decoction for the treatment of 37 cases of senile hypertension with left ventricular hypertrophy. Chin Pharm. 2015;24:75–77.
59. Hu M. Xuefu Zhuyu Decoction combined with western medicine for the treatment of resistant hypertension in the elderly: a randomized controlled study. J Pr Tradit Chin Intern Med. 2014;28:123–125.
60. Li MH, Luo CQ. Effect of Xuefu Zhuyu Decoction combination with atorvastatin calcium on homocysteine in elderly hypertensive patients. Chin Mod Doct. 2014;52:48–50.
61. Wang Y. Clinical Observation on Promoting Blood Circulation by Removing Blood Stasis Improve Blood Viscosity To Influence Diastolic Blood Pressure. Haerbin, China: Heilongjiang University of Chinese Medicine; 2011:1–44.
62. Liu YW. Long-term effect of promoting blood circulation by removing blood stasis therapy for the treatment of 45 cases of hypertension. Guangxin Chin Med. 2014;29:1213–1214.
63. Zhou L, Zhang JR, Wang Q. Effect of modified Xuefu Zhuyu Decoction in treating 60 cases of hypertension with qi deficiency and blood stasis syndrome. Front Med. 2014;4:336–337.
64. Fu JH, Pang ZR, Sang Y, et al. Effect of Xuefu Zhuyu Decoction combined with nimodipine for the treatment of 68 cases of essential hypertension. JinJi J Tradit Chin Med. 2003;23:12–13.
65. Liu YM. Clinical observation on modified Xuefu Zhuyu Decoction in treating hypertension. Xinjiang J Tradit Chin Med. 2014;32:10–12.
66. Lu X. Effect of Xuefu Zhuyu Decoction combined with captopril for the treatment of 30 cases of essential hypertension. Mod Med. 2001;17:839.
67. Guo JJ. Clinical observation on modified Xuefu Zhuyu Decoction in treating 64 cases of hypertension with blood stasis syndrome. Chin Health Care Nutr. 2013;10:5508–5509.
68. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14–26.
69. Mancia G, Fagard R, Narkiewicz K, et al., Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–1357.
70. Lawes CM, Vander HS, Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease. Lancet. 2008;371:1513–1518.
71. McManus RJ, Caulfield M, Williams B. National Institute for Health and Clinical Excellence. NICE hypertension guideline 2011: evidence based evolution. BMJ. 2012;344:e181.
72. Wang J, Feng B, Yang XC, et al. Tianma gouteng yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med. 2013;2013:706125.
73. Wang J, Feng B, Xiong XJ. Chinese herbal medicine for the treatment of obesity-related hypertension. Evid Based Complement Alternat Med. 2013;2013:757540.
74. Wang J, Yao KW, Yang XC, et al. Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med. 2012;714805.
75. Wang J, Xiong XJ. Control strategy on hypertension in Chinese medicine. Evid Based Complement Alternat Med. 2012;2012:294847.
76. Lu AP, Chen KJ. Chinese medicine pattern diagnosis could lead to innovation in medical sciences. Chin J Integr Med. 2011;17:811–817.
77. Wang J, Wang PQ, Xiong XJ. Current situation and re-understanding of syndrome and formula syndrome in Chinese medicine. Int Med. 2012;2:e1000113.
78. Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol Sci. 2005;26:558–563.
79. Wang J, Xiong XJ. Current situation and perspectives of clinical study in integrative medicine in China. Evid Based Complement Alternat Med. 2012;2012:e268542.

80. Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2014 update—a report from the American Heart Association. Circulation. 2014;129:e28–e292.

81. Naing C, Aung K. Prevalence and risk factors of hypertension in Myanmar: a systematic review and meta-analysis. Medicine (Baltimore). 2014;93:e100.

82. Catena C, Colussi G, Url-Michtisch M, et al. Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension. J Am Soc Hypertens. 2015;9:167–175.

83. Vyssoulis G, Karpanou E, Kyvelou SM, et al. Associations between plasma homocysteine levels, aortic stiffness and wave reflection in patients with arterial hypertension, isolated office hypertension and normotensive controls. J Hum Hypertens. 2010;24:183–189.

84. Wang Y, Chen S, Yao T, et al. Homocysteine as a risk factor for hypertension: a 2-year follow-up study. PLoS One. 2014;9:e108223.

85. Park B, You S, Jung J, et al. Korean studies on blood stasis: an overview. Evid Based Complement Alternat Med. 2015;2015:e316872.

86. Li SM, Xu H, Chen KJ. The diagnostic criteria of blood- stasis syndrome: considerations for standardization of pattern identification. Chin J Integr Med. 2014;20:483–489.

87. Chen KJ. Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy. Chin J Integr Med. 2012;18:891–896.

88. Lu L, Li HQ, Fu DL, et al. Rhubarb root and rhizome-based Chinese herbal prescriptions for acute ischemic stroke: a systematic review and meta-analysis. Complement Ther Med. 2014;22:1060–1070.

89. Shlomai G, Grassi G, Grossman E, et al. Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand? J Clin Hypertens (Greenwich). 2013;15:742–747.

90. Vernooij JWP, Graaf YVD, Nathoe HM, et al. Hypertensive target organ damage and the risk for vascular events and all-cause mortality in patients with vascular disease. J Hypertens. 2013;31:492–499.

91. Schillaci G, Verdecechia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580–586.

92. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010;31:883–891.

93. Cuspidi C, Macca G, Michev I, et al. Left ventricular concentric remodelling and extracardiac target organ damage in essential hypertension. J Hum Hypertens. 2002;16:385–390.

94. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97.

95. Vickers A, Goyal N, Harland R, et al. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials. 1998;19:159–166.

96. Chen W, Lin CD, Kang HJ, et al. Chinese herbal medicines for the treatment of Type A H1N1 Influenza: a systematic review of randomized controlled trials. PLoS One. 2011;6:e28093.